 |
|
Stents for Palliation of Obstructive Metastatic Colon Cancer—Invited Critique
Wilbur B. Bowne, MD;
Michael E. Zenilman, MD
Arch Surg. 2007;142(7):623.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Dr Karoui and colleagues present a timely, thought-provoking study comparing SEMS with operative management in the setting of obstructing colon cancer with unresectable distant disease. Their experience with this technique further underscores the potential efficacy, safety, and equivalency compared with palliative surgery.1 However, their enthusiasm stems mostly from demonstrating a significant benefit with decreased hospital stay, stoma formation, and time to chemotherapy—hence, less morbidity. Their proposed paradigm shift from palliative surgery to a less-is-more or bridging-treatment approach appears more relevant when considering that (1) palliative surgery delays administering systemic chemotherapy; (2) recent advances with systemic therapies have improved median survivals approaching 2 years; and (3) operative salvage can be offered in select patients with demonstrable tumor regression (downstaging) or without tumor progression—a distinct survival advantage.2-4
Less relevant is the actual impact of stent therapy on salvage resection and ultimate survival. Neither was . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Stents for Palliation of Obstructive Metastatic Colon Cancer: Impact on Management and Chemotherapy Administration
Mehdi Karoui, Antoine Charachon, Catherine Delbaldo, Jérome Loriau, Alexis Laurent, Iradj Sobhani, Jeanne Tran Van Nhieu, Jean Charles Delchier, Pierre-Louis Fagniez, Pascal Piedbois, and Daniel Cherqui
Arch Surg. 2007;142(7):619-623.
ABSTRACT
| FULL TEXT
|
